Detalhe da pesquisa
1.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet
; 402(10395): 41-53, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331369
2.
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
Future Oncol
; : 1-8, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861293
3.
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Invest New Drugs
; 41(3): 421-430, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37074571
4.
Therapeutic advances in pancreatic cancer.
Gastroenterology
; 144(6): 1316-26, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23622141
5.
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Cancer Discov
; 14(6): 982-993, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587856
6.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
J Immunother Cancer
; 11(6)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37286304
7.
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
EClinicalMedicine
; 58: 101917, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37090438